Receptor tyrosine kinases (RTKs) are membrane proteins regulating intercellular communication by controlling cell differentiation, proliferation, survival, and migration. 1 RTKs and their appending ligands have been shown to play crucial roles in the pathogenesis of glioblastoma (GBM). 2, 3 The heterogeneity and redundancy of several molecular pathways simultaneously involved in tumor progression and angiogenesis of GBM may limit the activity of most single-targeting agents. 4 Therefore, the concept of multitargeted therapy approaches, which inhibit multiple molecular signaling pathways simultaneously, seems an appealing treatment strategy for GBM.
Sunitinib malate (Sutent#, SU11248), an orally bioavailable, small-molecule inhibitor (SMI) of multiple receptor tyrosine kinases (VEGFR-1/-2/-3, PDGFR-a/-b, c-KIT, FLT3, RET and CSF-1R) with antiangiogenic and antitumor activities, 5, 6 demonstrated efficacy with acceptable tolerability in patients with metastatic renal cell carcinomas, 7 -9 gastrointestinal stromal tumors, 10, 11 and pancreatic neuroendocrine tumors. 12 In patients with GBM it was recently demonstrated that the effect of AZD2171 (cediranib), another oral multitargeted SMI with activity against pan-VEGFR, pan-PDGFR and c-KIT, was rapidly lost following drug interruption. 13 Therefore, the aim of this prospective multicenter phase II clinical trial was to evaluate the antitumor activity of a continuous once-daily dosing regimen of sunitinib in patients with first recurrence of supratentorial primary GBM.
Patients, Materials and Methods

Study Design
This prospective, multicenter, single-arm, phase II open-label clinical trial was approved by the ethical review committees at each of the 10 participating centers and was performed in accordance with the International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guidelines. All participants signed an approved informed consent before enrollment and complied with scheduled visits, treatment plans, laboratory tests, and other study procedures.
The primary study endpoint was a 6-month progression-free survival (PFS6) rate, defined as the percentage of participants who remained alive and progression free at 6 months after treatment initiation. Secondary study endpoints included objective response assessment, median progression-free survival (PFS), median overall survival (OS), 12-month OS rate, safety and toxicity, quality-of-life assessment, and translational molecular studies on the sunitinib target molecules in tumor and vascular endothelial cells by immunohistochemistry.
Safety evaluations throughout the study included a hematological and nonhematological adverse event (AE) assessment with severity graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE, V3.0), Eastern Cooperative Oncology Group (ECOG) performance score, and quality-of-life assessment.
The neuropathological diagnosis of a primary GBM (J. Hainfellner) and all study MRI scans (T. Gotwald) were centrally reviewed. In the case of discrepancy between the assessment of the independent reviewer and the local investigator, the assessment of the independent reviewer was given precedence.
Participant Eligibility
Eligible for the study were patients with a first recurrence of a histologically proven supratentorial GBM diagnosed by MRI according to Macdonald criteria 14 or by histological confirmation following re-resection. A detailed description of all inclusion and exclusion criteria and baseline evaluations is provided in Supplemental  Table S1 .
Study Treatment
Sunitinib was provided by Pfizer Inc. as an oral drug in 12.5 mg capsules. At study enrollment, all participants were treated with sunitinib 37.5 mg in a continuous once-daily dosing regimen. The dosage was titrated up to 50 mg per day or down to 25 mg per day or 12.5 mg per day in steps of 12.5 mg depending on toxicity after the first 2 treatment weeks. Dose escalation to 50 mg per day was considered for participants who experienced no or mild (grade ≤1) nonhematologic adverse events (AEs) or mild to moderate (grade ≤2) hematologic AEs. Participants who experienced grade 3 or 4 AEs stopped treatment until the AE severity decreased to grade ≤1 for nonhematologic AEs or grade ≤2 for hematologic AEs and then resumed treatment at either the same or a lesser dose per the investigator's discretion. Participants with a treatment interruption over 3 weeks were discontinued from the study. Treatment was otherwise continued until tumor progression.
Treatment Response Evaluation
All participants were clinically monitored by physical and neurological examinations (Neurology Medical Research Council Scale, ECOG performance status), laboratory testing, and quality-of-life assessments (EORTC QLQ-C30 V3.0 15 and QLQ-BN20 16 ), which were performed at baseline, weeks 1 and 2, and every 2 weeks thereafter until tumor progression. Cardiac function assessment (ECG, transthoracic echocardiography) and MRI scans were carried out every 8 weeks until tumor progression. In the event of clinical signs of neurologic progression during treatment, the MRI had to be conducted within 1 week.
MRI scans were conducted at each participating center according to standard sequences, including T1 pre-and postcontrast, T2 fluid-attenuated inversion recovery, and diffusion weighted imaging. Objective response evaluation was performed according to Macdonald criteria, 14 defined as clinical and image-guided complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD).
Tissue Biomarker Analysis
Formalin-fixed paraffin-embedded (FFPE) tissue, derived from surgery of the primary tumor, was obtained from 35 participants. Serial whole sections were studied for the protein expression of the sunitinib target molecules VEGFR-1/-2/-3, PDGFR-a/-b, and c-KIT. CD31 staining was carried out for the proof of sufficient vascular density for neuropathological evaluation. Additional analysis for IDH1-R132H mutation and O6-methylguanine-methyltransferase (MGMT) promoter methylation was performed for further molecular characterization of GBM.
Immunohistochemical staining was performed according to the manufacturer's standard protocols at the Institute of Pathology, Medical University of Graz. Primary antibodies, purchased from different suppliers and working dilutions, are provided in detail in Supplemental Table S2 . Neuropathological evaluation was carried out by 2 independent, experienced and board-certified Hutterer et al.: Continuous daily sunitinib in glioblastoma neuropathologists, who analyzed the immunostaining pattern and intensity of tumor and vascular endothelial cells. A semiquantitative immunohistochemistry scoring system was applied as previously described. 17 MGMT promoter methylation was analyzed from 33 participants either by a pyrosequencing methylation assay from fresh frozen tissue (n ¼ 9; PyroMarkQ24 MGMT Kit, Qiagen; Institute of Neuropathology, Charité -Universitä tskrankenhaus Berlin, Germany) according to the manufacturer's standard protocols or a methylation-specific polymerase chain reaction (MSP) from formalin-fixed paraffin-embedded tissue (n ¼ 24; Department of Neuropathology, Institute of Pathology, University of Heidelberg, Germany) as previously described. 18 
Data and Statistical Analysis
The primary study endpoint of this single-arm phase II clinical study was PFS6. In 1999, Wong et al. 19 reviewed 8 consecutive phase II chemotherapy trials and reported a PFS6 rate of 15%. On the background of the missing efficacy data on sunitinib in glioblastoma patients, we first reviewed clinical trials on bevacizumab in highgrade glioma patients, which reported PFS6 rates between 38% and 46%. 20, 21 Therefore, a sample size of 40 participants was required to test the null hypothesis that the true response rate was ≤15% (historical data) versus the alternative hypothesis that the true response rate was ≥35% (treatment group), assuming a 2-sided significance level of 0.95, a power of 90%, and a drop-out rate of 15%. Due to the planned tissue biomarker analyses, a final study population of 80 participants with an interim analysis after 40 participants was determined. If 8 of the first 40 participants were stable at 6 months, the trial would continue to 80 participants.
Progression-free survival (PFS) was defined as time from study entry to disease progression on MRI. Overall survival (OS) was defined as time from study entry to death from any cause. Participants who were still alive at databank closure were censored until last known follow-up. Participants with a PFS ≥6 months on sunitinib treatment were defined as sunitinib responders.
The statistical significance of differences in values between the groups was calculated with the Mann-Whitney U test (MWU test).
Associations of categorical parameters were tested using the chisquare test. PFS and OS curves were summarized by the KaplanMeier method. The univariate and multivariate Cox proportional hazards model (forward stepwise procedure, 95% confidence interval [CI]) were used to assess the relationship between outcome and time-to-event endpoints or molecular parameters. Quality-of-life data analysis was based on mixed linear models comprising scores as dependent variables and time since baseline as fixed effect. The models included a random intercept on patient level and a first-order autoregressive covariance matrix. Statistical analysis was done using SPSS 20.0 software (SPSS Inc.) and P values of ,.05 were considered statistically significant. Table 1 . Participant disposition is presented in detail in Supplemental Table S3 .
Results
Participant Characteristics and Participant Disposition
Treatment Outcomes
An interim analysis was performed after enrollment of 40 participants. Only 5 participants (12.5%; 95% CI, 2.5% -22.5%) had PFS ≥6 months, and 24 participants (60.0%; 95% CI, 45.0% -75.0%) presented with clinical and/or radiological progressive disease within 8 weeks. Therefore, the primary endpoint of the study, Responder on first-line treatment ¼ PFS ≥12 months from first diagnosis to study enrollment. c Two participants (5%) discontinued sunitinib treatment due to toxicity (fatigue/asthenia and myelosuppression). d One participant (2.5%) was lost to follow-up; the death dates are unknown for the 2 participants,(5%) who died.
Hutterer et al.: Continuous daily sunitinib in glioblastoma predefined by a PFS rate at 6 months of 35% for continuation of the trial, was not reached, and further recruitment was terminated. Detailed participant treatment outcomes are presented in Table 2 . Thirty eight participants (95.0%) completed the primary study endpoint as defined per protocol. Two participants (5.0%) discontinued the study treatment prematurely after 0.5 and 3.8 months due to AEs (fatigue/asthenia and myelotoxicity). Two participants (5%) were alive, and 37 participants (92%) had died at study evaluation. One participant was lost for follow-up after disease progression. The date of death was not available for 2 participants (5%) who died.
The median PFS for the study population was 2.2 months (range, 0.5 -41.4; 95% CI, 1.8 -3.3). After 8 weeks on sunitinib, no radiographic responses (CR, PR) were detected; the best response was stable disease. Responders on sunitinib, predefined by a PFS ≥6 months on treatment (n ¼ 5, 12.5%), showed a longer median PFS of 16.0 months (6.4, 7.3, 16.0, 17.0, 41.4 mo; 95% CI, 6.4 -41.4) compared with sunitinib nonresponders with a median PFS of 1.8 months (range, 1.0 -4.3; 95% CI, 1.6 -2.3). Median OS for the study population was 9.2 months (range, 1.7 to 49.2; 95% CI, 6.6 -11.9); the 12-month OS rate was 27.5% (95% CI, 13.5% -41.5%]. Sunitinib responders showed a median OS of 46.9 months (range, 21.2 -49.2; 95% CI, 11.9 -49.2) compared with sunitinib nonresponders with a median OS of 8.1 months (range, 1.7 to 18.4; 95% CI, 5.4 -10.1). Two participants (5%) from the sunitinib responder subgroup were still alive after a follow-up period of 60 months.
In view of the impressive overall survival of some study participants, the post-sunitinib salvage therapies are presented in detail in Supplemental Fig. S1 . After tumor progression on sunitinib, 17 of the total study population (42.5%; 2 sunitinib responders, 15 sunitinib nonresponders) were treated only by supportive care. Twenty-three participants (57.5%) received third-line treatment including bevacizumab (BEV), temozolomide (TMZ), or CCNU chemotherapy regimens (Supplemental Fig. S1A ). Three of 17 BEVtreated participants (17.6%, only sunitinib nonresponders) had PFS ≥6 months, and 8 of 17 (47.1%) participants showed PFS between 3 and 6 months. Different fourth-line treatment approaches were carried out for 11 participants (Supplemental Fig. S1B ). The 3 sunitinib responders received BEV +/-CPT-11, resulting in prolonged tumor control of ≥3 months in 2 of these 3 participants.
Safety and Toxicity
Most treatment-related AEs were mild or moderate in severity (grade 1 or 2). No grade 5 AE (death) was observed. A detailed description of treatment-related AEs is provided in Table 3 .
Participant-reported Outcomes
Thirty-six participants completed the EORTC QLQ-C30/QLQ-BN20 questionnaire at baseline. Further quality-of-life assessments were available at 4-week follow-up in 31 participants, at 8-week follow-up in 15 participants, at 12-week follow-up in 11 participants, and at 16-week follow-up in 8 participants. Analysis was limited to 16 weeks due to a low number of participants at later follow-up time points.
When compared with a general population, large differences (.20 score points) at baseline were found for social functioning, role functioning, cognitive functioning, fatigue, and financial impact. 22, 23 From baseline to 16-week follow-up, the following scales deteriorated significantly: physical functioning Table S4 ).
Comparison of Sunitinib Responders with Nonresponders
The analysis of several clinical parameters of sunitinib responders and nonresponders by chi-square test is provided in Table 4 and shows a comparable distribution of age (P ¼ .192, age ,60 vs ≥60 years); gender (P ¼ .082, female vs. male), ECOG (P ¼ .157, ECOG 0/1 vs ECOG 2), resection type at first diagnosis (P ¼ .496, gross total/subtotal vs partial resection), and resection at first recurrence (P ¼ .633, yes vs no). Comparison of responders on firstline treatment (n ¼ 11), predefined by a PFS ≥12 months from first diagnosis to study enrollment, revealed that only 1 participant (20.0%) of the sunitinib responder subgroup was also a responder on first-line treatment compared with 10 participants (29.0%) of the sunitinib nonresponder subgroup (P ¼ .731). In addition, the distribution of participants with or without MGMTpromoter methylation was not different between sunitinib responders and nonresponders (P ¼ .451). Univariate Cox regression analysis was used to assess the relationship between the clinical parameters and participants outcome on sunitinib treatment, which revealed no statistically significant association (Table 5) .
Translational Molecular Studies
FFPE tissue from surgery of the primary tumor was eligible for translational molecular studies in 35 participants, including all 5 sunitinib responders. IDH1-R132H immunohistochemistry was negative in all glioma tissues, confirming a homogeneous study population of IDH1-R132H mutation-negative primary glioblastoma participants. CD31 staining confirmed high vascular density for tumor vessels analysis. MGMT promoter methylation was found in 11 (33%) of 33 evaluable participants. Immunohistochemical staining for the protein expression of the sunitinib target molecules VEGFR-1/-2/-3, PDGFR-a/-b, and c-KIT distinguished between tumor (T+) and vascular endothelial cells (V+) according to the immune reactive score. VEGFR-1 and c-KIT were not expressed in tumor cells. Positive tumor-cell staining was detected for VEGFR-2 (n ¼ 18, 51%), VEGFR-3 (n ¼ 17, 49%), PDGFR-a (n ¼ 25, 71%), and PDGFR-b (n ¼ 14, 40%). Vascular cells expressed all receptor subtypes including VEGFR-1 (n ¼ 6, 17%), VEGFR-2 (n ¼ 26, 74%), VEGFR-3 (n ¼ 25, 71%), PDGFR-a (n ¼ 18, 51%), PDGFR-b (n ¼ 7, 20%), and c-KIT (n ¼ 17, 49%).
The univariate Cox regression analysis was used for comparison of the survival distributions of sunitinib responders and nonresponders dependent on sunitinib target molecule expression patterns. Only the expression of c-KIT in vascular endothelial cells ( (Fig. 2A ), but not with OS ( Table 5 ). The absence or low expression of PDGFR-a in tumor cells (Fig. 1B) was associated with improved PFS (P ¼ .043; hazard ratio [HR], 0.383; 95% CI, 0.151-0.969) (Fig. 2B) but not with OS (Table 5 ). All other investigated RTK expressions, as well as MGMT promoter methylation status (Fig. 2C) , failed to predict a favorable PFS or OS on sunitinib treatment. Multivariate Cox regression analysis revealed that only positive c-KIT expression in vascular endothelial cells was an independent molecular marker for prolonged PFS (c-KIT [V+0]) (P ¼ .017; HR, 2.564; 95% CI, 1.180-5.570); PDGFR-a (T+) (P ¼ .072) (Table 5) . Finally, only MGMT promoter methylation (P ¼ .028; HR, 2.505; 95% CI, 1.044-6.008) (Fig. 2F) , but not vascular c-KIT (P ¼ .213) (Fig. 2D) or tumoral PDGFR-a expression (P ¼ .469) (Fig. 2E) , was predictive for prolonged PFS during first-line treatment. 
Hutterer et al.: Continuous daily sunitinib in glioblastoma
Discussion
In this prospective multicenter phase II clinical trial,, we investigated the antitumor activity of continuous single-agent sunitinib in 40 participants with a first recurrence of a supratentorial primary GBM. Since previous studies on multitargeted SMIs with antiangiogenic properties have indicated rapid loss of treatment effects after drug discontinuation, 13 a continuous toxicitydependent, dose-adapted treatment regimen was the rationale for the clinical trial design.
The major findings of the study included minimal antitumor activity of this continuous sunitinib schedule with a median PFS of 2.2 months, a median OS of 9.4 months, and substantial dosedepending drug toxicity at higher doses associated with decreasing quality of life. In a subgroup of 5 participants (12.5%), however, sunitinib treatment resulted in distinct prolonged stable disease with a median PFS of 16.0 months and a median OS of 46.9 months. Importantly, high c-KIT expression in the primary tissues of vascular endothelial cells was significantly and independently associated with improved PFS.
So far, 3 phase II clinical trials investigating sunitinib in recurrent high-grade gliomas have been reported. 24 -26 Among these trials (summarized in Supplemental Table S5 ), different sunitinib treatment regimens were used (continuous daily, 4w/6w regime), and the population size varied from 15 to 32 participants. In comparison with the presented study, the key inclusion criteria of these previous trials were less rigid in terms of glioma histology (grade III and grade IV gliomas), recurrence status (first to second, first to third, any recurrence), and pretreatment (bevacizumab-naive, bevacizumab-resistant). Recently, Kreisl et al. 24 studied continuous daily sunitinib in glioblastoma patients at any recurrence stratified by prior bevacizumab (BEV) exposure. In line with our results, in the BEV-naive cohort (n ¼ 32) PFS6 was 10.4% (median PFS, 1.1 mo; median OS, 9.4 mo). Neyns et at. 26 conducted a phase II trial on 21 BEV-naive patients with high-grade glioma at first or second recurrence using a continuous daily sunitinib regime. There were also no objective responses, and all patients progressed by the first response evaluation at 8 weeks. Pan et al. 25 reported a phase II trial studying single-agent sunitinib using a 4 of 6 week treatment (4w/6w) regimen in 30 high-grade glioma patients at any recurrence with a PFS6 of 16.7%, a median PFS of 1.4 months, and a median OS of 12.1 months for the GBM subgroup. Therefore, the strengths of this clinical trial are the homogenous study population consisting of 40 participants with a first recurrence of a primary IDH1-R132H mutation negative GBM and a follow-up period of up to 5 years.
Taken together in all phase II clinical trials, sunitinib showed insufficient antitumor activity in high-grade glioma patients with several possible explanations for these disappointing results: First, higher doses of continuous sunitinib are fairly toxic and poorly tolerated by glioma patients.
Second, penetration into CNS tumors could be an issue. However, Plotkin et al. 27 recently reported that intratumoral sunitinib concentrations were even higher compared with plasma. Similar findings were found for the anti-EGFR small-molecular inhibitor gefitinib. Gefitinib treatment resulted in 20-times higher drug concentrations in resected GBM tissues compared with plasma, but no significant effects on 12 intracellular pathway constituents were observed except for EGFR-dephosphorylation. 28 Third, tumor cells themselves may develop acquired drug resistance, which has already been shown for sunitinib using an in vivo model. 29 The most profound difference between sunitinibsensitive and sunitinib-resistant tumors was the expression of several phosphorylated proteins involved in intracellular signaling, in particular an upregulation of phospholipase C-g1 indicating an activation of alternative pro-survival pathways involved in tumor growth escape mechanisms.
Despite these overall negative results of clinical phase II studies on sunitinib in high-grade gliomas, subgroups of participants presented with distinctly longer PFS and stable disease, also presented in Supplemental Table S5 . In the presented clinical trial, we observed 5 sunitinib responders, predefined by a PFS ≥6 months and stable disease on sunitinib, with a PFS up to 41.6 months. Importantly, prolonged PFS was not associated with other independent prognostic parameters such as age, ECOG performance score at first recurrence, type of surgery at first diagnosis, surgery at recurrence, first-line treatment response, or MGMT promoter methylation. Interestingly, participants with prolonged PFS were Hutterer et al.: Continuous daily sunitinib in glioblastoma observed in both sunitinib treatment regimens, the continuous daily as in our study and the 4 of 6 week drug schedule, 24, 25 indicating that prolonged disease control does not require continuous drug exposure.
In this context, the exclusion of pseudo-progression, mimicking early tumor progression just during or shortly after radiotherapy/ chemotherapy (up to 12 weeks after radiation ends) leading to prolonged disease control independent of sunitinib treatment, is of importance. 30 Currently, the only methods of distinguishing pseudo-progression from early tumor progression are re-section with histological evaluation of the tumor-suspect tissue or sequential follow-up MRI scans because the changes on MRI related to pseudo-progression decrease in size over time. 31, 32 In the presented study, re-resection of the first GBM recurrence was performed in 3 of 5 sunitinib responders (60%) confirming tumor progression. The remaining 2 participants developed their first tumor progression 7.5 and 8.2 months after initial diagnosis, and both showed a prolonged stable disease under sunitinib treatment, which makes pseudo-progression also unlikely.
Because sunitinib has direct antitumoral and antiangiogenic activity, we investigated the protein expression patterns of the sunitinib target molecules in tumor and vascular endothelial cells by immunohistochemistry. Only the expression of c-KIT in vascular endothelial cells was independently associated with prolonged PFS and was neither predictive for response to first-line treatment nor associated with improved OS, which could be explained with the use of effective rescue regimens. Post-sunitinib salvage therapy analysis revealed that BEV-containing chemotherapy regimens were effective after sunitinib failure in sunitinib responding and nonresponding participants (Supplemental Fig. S1 ). This observation indicates that prior exposure to VEGF receptor inhibitors may not preclude response to BEV, as already previously reported by Goldlust et al. 33 c-KIT (CD117) is a proto-oncogene that encodes for a receptor tyrosine kinase, which binds the stem cell factor (SCF) for activation. 34 In vivo SCF is secreted by glioma cells and normal neurons, which are activated by infiltrating glioma cells. 35 c-KIT is predominantly expressed in brain microvascular endothelial cells, indicating paracrine mechanisms driving tumor cell-mediated angiogenesis and tumor growth. 35, 36 Consistent with a potential role in angiogenesis, c-KIT is also expressed on circulating endothelial precursor cells, which originate in the bone marrow and are recruited into vessels during angiogenesis. 37, 38 Furthermore, nonhematopoietic and noncirculating tissue resident vascular endothelial stem cells, capable of undergoing rapid clonal expansion and generating functional blood vessels that connect to host circulation in vivo, have also been reported to express c-KIT that is involved in angiogenesis. 39 Therefore, it is tempting to speculate that sunitinib may exert influence on the complex functions of SCF/c-KIT mediated tumor angiogenesis resulting in prolonged disease control.
The limitations of the translational molecular studies, however, are the study design of a single-arm phase II clinical trial missing a control group, the small number of 40 participants, and that these studies had to be performed on the primary and not on the tumor tissue at first recurrence.
In summary, continuous daily sunitinib demonstrated minimal activity in participants with primary GBM at first recurrence, but substantial toxicity when given at higher doses. High vascular c-KIT expression may define a subgroup of patients with a benefit from sunitinib treatment by achieving prolonged PFS, which requires further confirmatory translational studies.
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